國藥現代(600420.SH):擬受讓氨氯地平阿託伐他汀鈣片、奧美沙坦酯氫氯噻嗪片上市許可及相關權益
格隆匯11月11日丨國藥現代(600420.SH)公佈,為貫徹落實公司中長期發展戰略,豐富公司心腦血管領域產品線,公司與吉林德商就其所研發的氨氯地平阿託伐他汀鈣片、奧美沙坦酯氫氯噻嗪片分別簽署了《藥品上市許可轉讓合同》。吉林德商將其正在申報註冊的氨氯地平阿託伐他汀鈣片(5mg/10mg 、5mg/20mg)、 研究開發階段的奧美沙坦酯氫氯噻嗪片(20mg/12.5mg)上市許可及相關權益轉讓予公司,並提供技術轉移服務。其中:氨氯地平阿託伐他汀鈣片上市許可轉讓費用總額最高不超過人民幣2500萬元,奧美沙坦酯氫氯噻嗪片上市許可轉讓費用總額為人民幣1900萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.